Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers

Press

Announcement

April 5, 2024

Iambic Rhythm: AI Drug Developer Enters the Clinic, Targeting HER2 Cancers

Related articles

Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026

October 26, 2026

Iambic Presents Updated IAM1363 Clinical Data at ESMO 2026, Showing Durable Responses with a Favorable Tolerability Profile in Heavily Pretreated Participants with HER2-Driven Cancers

Iambic Announces Pricing of Initial Public Offering

October 14, 2026

Iambic Announces Pricing of Initial Public Offering

October 5, 2026

Iambic Submits IND for a Potentially Brain-Penetrant KIF18A Inhibitor IAM217, Its Second Wholly Owned AI-Discovered Candidate

Let's work together

Leverage the Iambic discovery process for your program. Reach out to us at partnerships@iambic.ai.